Bristol Myers sues Amgen over proposed Opdivo biosimilar
By Blake BrittainBristol Myers Squibb NYSE:BMY and Ono Pharmaceutical TSE:4528 have sued Amgen NASDAQ:AMGN in Delaware federal court, seeking to block Amgen's proposed U.S. biosimilar of their blockbuster cancer immunotherapy drug Opdivo.The case is Bristol-Myers Squibb Co. v. Amgen Inc., U.S. Dist…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.